Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jared Weiss is an Associate Professor of Clinical Research for Hematology/Oncology at the University of North Carolina School of Medicine in Chapel Hill, NC. He completed fellowship in Hematology and Oncology at the University of Pennsylvania and residency in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, MA. He received his Doctor of Medicine at Yale University School of Medicine in New Haven, CT and his B.S. in neuroscience at Brown University, in Providence, RI.

Lung Cancer Video Library - Lung Cancer Demographics/Epidemiology
Author
Jared Weiss, MD
Image
 

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the demographics and epidemiology of lung cancer.

 

Transcript

I’m going to speak to you today about lung cancer demographics.

Lung cancer is just behind heart disease for the leading cause of death amongst Americans.

Within cancer, lung cancer causes the overwhelming majority of the death.

For both men and women, lung cancer is the second most incident cancer.

However because of that highly deadly nature of lung cancer we talked about,

it actually drives the highest death rate in both men and in women.

Lung cancer can affect anyone: only 44% of our patients are current smokers, about the similar number have previously smoked and quit, and 10-15% are never smokers. However, given how deadly lung cancer is, this drives nonsmoking lung cancer to be one of the greatest causes of suffering and death amongst cancers.

So just to put this into perspective, I have five month old twin daughters. They will never smoke a day in their lives because they will know that I will kill them if they do. Assuming that’s true, that they never smoke a day in their lives, my daughters are far more likely to die of nonsmoking lung cancer than they are to die of breast cancer.

 

Lung cancer can also affect anyone regardless of age. You can see here the spread of lung cancer — you can see that the bulk of presentation is at an older age, our median age of presentation is about 71 years, but you can see if you look at the left side of this table that it actually does have real incidence in younger patients. I have treated 20 and 30 year old patients for lung cancer. It is unfortunately quite real. I thank you for your kind attention.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!
Image
Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón
Video
¡El vídeo completo bajo demanda está disponible para verlo!

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
That's beautiful Linda…
By JanineT GRACE … on
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on